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Background: Women of child bearing age with multiple sclerosis (MS) must carefully
consider treatments when planning a family, since disease modifying drugs (DMDs) are
contraindicated during pregnancy.
Objectives: This questionnaire-based study aimed to improve understanding of the
effect of family planning on treatment decisions in female, Swiss MS patients.
Methods: Female patients with MS (aged 18–55 years) participated in the 26-question
survey between September 2014 and August 2015. Information captured included
patient background, family planning status, treatment course, and previous pregnancies.
Results: In total, 271 questionnaires distributed from 15MS centres were returned for
analysis. Of these, 250 (92.3%) participants received DMD therapy and 106 (39.1%)
wanted children or were pregnant. Significantly more patients with a short-term plan
to conceive within 2 years were treated with injectables (19/54) compared with those
without a plan to conceive (19/108; p = 0.013). A proportionally greater number of
women not planning to conceive took oral (34/108) or infusion therapies (41/108)
compared with those with a short- (13/54 and 16/54, respectively) or medium-term (after
2 years or more; infusion therapy only, 14/44) plan to conceive.
Conclusion: The study highlights that pregnancy remains an important yet unresolved
concern in the treatment of MS patients. Nearly all women received DMD treatment, and
type of DMD treatment was influenced by family planning, with significantly more women
with a short-term plan to conceive using injectables.
Keywords: pregnancy, family planning, multiple sclerosis, disease modifying drugs, treatment decision
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INTRODUCTION
In Switzerland, approximately 10,000 patients had MS in 2016
(1). The disease preferentially affects women and in recent
decades, the ratio of women to men who develop the disease
has risen (from 2.3:1 to 3.5:1) (2). MS is most often diagnosed
between the ages of 20 and 40 years, therefore, many women with
MS are of childbearing age and may plan to conceive (3).
Fertility and the course of pregnancy are not affected by MS
(4). However, problems arise regarding the effective treatment
of MS using disease modifying drugs (DMDs) in women who
plan to become pregnant because none of the DMDs are
officially approved for use during pregnancy in Switzerland. In
clinical practice, treatment with some DMDs is stopped before
pregnancy, some are given until pregnancy occurs, and some
DMDs may be used during pregnancy after an individual risk-
benefit analysis (5).
Thus far, studies suggest that use of injectable platform DMDs
in early pregnancy hasminimal effect on pregnancy outcomes (6–
12). Recent registry data investigating the effects of interferon β
(IFN β) exposure during early pregnancy showed there were no
or minor differences in birth weight, birth length, premature
birth, or other adverse pregnancy outcomes, compared with
women with no DMD exposure (6). Similarly, glatiramer acetate
(GA) has shown no known effects on pregnancy outcomes (7).
Data for newer treatments have also emerged on this
topic. In a cohort of 355 pregnancies exposed early on to
natalizumab, outcomes appeared unchanged except the major
birth defect rate, which was higher than that observed in the
general population. No specific pattern of birth defects was
observed that would suggest a drug effect (13). In addition,
some newborns, whose mothers were exposed to natalizumab
during the third trimester of pregnancy, displayed haematologic
alterations such as thrombocytopaenia and anaemia (14). A
safety database with fingolimod that recorded 324 live births,
found no increase in incidence of congenital malformations
when compared with the general population (15). However, a
smaller study that reported birth outcomes from 41 pregnancies,
suggested fingolimod exposure during pregnancy was associated
with a higher occurrence of foetal abnormalities, which included
a case of acrania and tetralogy of Fallot (16). Interestingly,
teriflunomide was also shown to have no effect on the
occurrence of birth defects in 83 pregnancies (17), despite this
drug causing reproductive toxicity in animals (18). However,
the statistical power of this study was not sufficient to
establish absolute teratogenicity (17), a factor that should be
considered in all studies that evaluate drug effects on pregnancy
outcomes (19).
Since treatment choice may be influenced by pregnancy plans,
women withMSmust weigh the possibility of a pregnancy during
treatment, against the risk of disease progression without MS
treatment when planning to conceive (5). Here we present the
Swiss Women with MS patient survey, which as the first of
its kind, aimed to improve the understanding of the effect of
family planning on treatment decisions in women with MS of
child bearing age, the influencing factors, and how the subject is
addressed in the context of their treatment.
METHODS
Patients
Between September 2014 and August 2015, the Women with MS
patient survey was conducted in Switzerland across 15 specialised
MS centres. To obtain a cohort that best represented the Swiss
MS population, eight centres were hospital-based and seven
were private practices. Inclusion criteria were female patients
with McDonald MS 2010 (20), aged 18–55 years. Child-bearing
age was categorised as aged between 18–45 years; women aged
>45–55 years were included, given that part of this survey was
retrospective (see below, questions 19–26). Patient inclusion was
also independent of disease course, DMD treatment and family
planning status. The main exclusion criteria were any diseases
or conditions that would affect the adequate performance of the
study procedures.
Questionnaire
The questionnaire was designed by an independent company
(Appletree CI Group AG [ACG+], Winterthur, Switzerland)
for paper and online data collection in German, French and
Italian languages. Printed questionnaires were transmitted to
the MS centres in sealed envelopes; each had a unique study
number that was associated with an MS centre to facilitate
questionnaire tracking. The questionnaires were distributed
to eligible patients during routine appointments at the MS
centres. Questionnaires answered on paper were sent directly
to ACG+ in post-paid envelopes. Alternatively, patients could
answer questionnaires online using a unique code that was
printed on the questionnaire envelopes. The exact return rate
was not evaluated and reminders were not sent due to the
anonymised nature of the questionnaire. The patient survey
contained 26 multiple choice questions that were answered
anonymously. Questions 1–7 determined the participants’
background and circumstances. The disease course of each
participant was provided by their neurologists (question 5).
Questions 8–18 established the treatment course, disease
state and family planning status of the participants. The
remaining questions (19–26) captured information regarding
previous pregnancies. In order to evaluate comprehensibility, the
questionnaire was given to 10MS patients prior to commencing
the study, however no major adaptions were required. The
questionnaire was not validated before the study was initiated.
The final version of the questionnaire in English is shown as
Supplementary Material.
The study design was discussed with the Ethics Committee
of Bern, Switzerland, and a decision was made that no written
patient information or patient consent forms were required given
that the questionnaire was anonymised.
Statistical Analysis
Key variables in this study, upon which the analysis was based,
included the patients’ family planning status (question 8) and
treatment choice and pregnancy (question 12). Patients were
stratified into groups according to their plans to conceive,
which included no plan, short-term plan (i.e., planning to
conceive within 2 year) and medium-term plan (i.e., planning
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to conceive after 2 years or more). For the analysis, DMD
treatments were categorised into the following groups: injectables
(subcutaneous [sc] interferon β-1a [sc IFN β-1a], intramuscular
[im] IFN β-1a, sc IFN β-1b and glatiramer acetate [GA]),
infusion (natalizumab), oral (fingolimod and teriflunomide) and
“other” therapies. Dimethyl fumarate (DMF) was not specifically
included because it was approved in Switzerland near the end of
2014 and therefore was not significant to this survey, since no
participants were using the drug. Further key variables included
age category (<20, 20–30, 31–40, 41–45, >45 years), time since
diagnosis (0–3, 3–5, 5–10, >10 years), treatment with DMD (yes
or no) and importance of therapy in regards to pregnancy (very
important, important or not important).
The questionnaire data were mostly analysed descriptively.
However, the responses to question 10 were analysed by applying
the Pearson’s chi-squared test on the respective contingency
tables. The test was performed in SPSS (SPSS 22 under the
operating system Windows 7 Professional, Service Pack 1) to
determine statistical differences between groups (significance
level 0.05, 2-sided). The survey sample size of 271 was sufficient
to represent a population of ≤100,000 with a confidence interval
of±5% on a confidence level of 90%.
RESULTS
Patient Characteristics
In total, 271 questionnaires were returned for analysis (252
questionnaires were answered on paper; and 19 online).
Of these, 177 (63.5%) questionnaires were answered by
patients treated in hospital and 94 (34.7%) questionnaires
by patients treated by practice based neurologists. Within
the study population, 79.3% (215/271) of patients were of
childbearing age (18–45 years) and the majority (91.9%;
249/271) were diagnosed with relapsing remitting multiple
sclerosis (RRMS). In addition, 39.1% (106/271) were pregnant
or wanted a child (Table 1). For those of childbearing age
(18–45 years), 48.4% (104/215) wanted children or were
pregnant, whereas 38.1% (82/215) had no plan to conceive
and 13.5% (29/215) did not answer the question (see below,
Table 5).
The majority of survey participants were receiving DMD
treatment (92.3%, 250/271). Of those receiving treatment, 21.6%
(54/250) were taking injectable therapies (sc IFN β-1a [5.2%,
13/250], im IFN β-1a [3.2%, 8/250], sc IFN β-1b [6.4%,
16/250] and GA [6.8%, 17/250]), 30.4% (76/250) oral therapies
(fingolimod [28.4%, 71/250] and teriflunomide [2%, 5/250]),
35.2% (88/250) infusion therapy (natalizumab), and 12.8%
(32/250) were using “other” treatments.
The importance of specific factors in context of the
disease were scored by patients on a scale of 1–5 (where
1 = not very important and 5 = very important). For
participants in the whole population or planning to
conceive, there was little or no difference in the mean
score (± standard deviation) for delay in disability (total
population, 4.8 [± 0.73]; women planning to conceive, 4.8
[± 0.61]), independence (4.8 [± 0.66]; 4.8 [± 0.59]), relapse
free (4.7 [± 0.73]; 4.8 [± 0.60]), partnership (4.4 [± 1.02];
TABLE 1 | Patient characteristics in the study population (N = 271).
Parameter n (%)
AGE DISTRIBUTION, YEARS
<20 3 (1.1)
20–30 77 (28.4)
31–40 97 (35.8)
41–45 38 (14.0)
>45 52 (19.2)
Unspecified 4 (1.5)
DIAGNOSIS
CIS 7 (2.6)
RRMS 249 (91.9)
SPMS 6 (2.2)
Unspecified 9 (3.3)
PLAN TO CONCEIVE
No plan 117 (43.2)
Currently pregnant 4 (1.5)
Short-term 58 (21.4)
Medium-term 44 (16.2)
Unspecified 48 (17.7)
DMD TREATMENT
Yes 250 (92.3)
No 21 (7.7)
DMD TREATMENT (n = 250)
im IFN β-1a 8 (3.2)
sc IFN β-1a 13 (5.2)
sc IFN β-1b 16 (6.4)
Fingolimod 71 (28.4)
GA 17 (6.8)
Natalizumab 88 (35.2)
Teriflunomide 5 (2.0)
“Other” 32 (12.8)
n, number; CIS, clinically isolated syndrome; RRMS, relapsing remitting multiple sclerosis;
SPMS, secondary progressive multiple sclerosis; DMD, disease modifying drug; im,
intramuscular; sc, subcutaneous; IFN, interferon; GA, glatiramer acetate.
4.5 [± 0.81]) and work (4.1 [± 1.04]; 4.2 [± 0.88]). Family
planning was more important to women planning to
conceive (4.3 [± 0.83]), compared with the whole population
(3.2 [± 1.61]).
Baseline characteristics of those patients planning to conceive
(short- [within 2 years] or long-term [after two 2 years or more])
are shown according to age group in Table 2. These data include
the type of MS, choice of DMD and importance of treatment in
relation to pregnancy.
Role of Neurologists in Family Planning
For all patients (N = 271), the frequency at which the topic of
pregnancy was addressed by their neurologists was captured by
the survey. For 16.6% (45/271) of patients, neurologists initiated
the subject of pregnancy at each consultation, whereas 25.5%
(69/271) did so sporadically, 27.7% (75/271) did so when the
patient asked and 25.8% (70/271) did not raise the topic of
pregnancy at all.
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TABLE 2 | Characteristics of patients planning to conceive in accordance with age.
Age, years, distribution, n (%)
<20 20–30 31–40 41–50 >45 Unspecified Total
n = 2 n = 63 n = 32 n = 3 n = 1 n = 1 n = 102
DIAGNOSIS
CIS 1 (50) 3 (4.8) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 5 (4.9)
RRMS 1 (50) 60 (95) 30 (94) 2 (67) 1 (100) 1 (100) 95 (93)
SPMS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Unspecified 0 (0.0) 0 (0.0) 1 (3.1) 1 (33) 0 (0.0) 0 (0.0) 2 (2.0)
CHOICE OF DMD
im IFN β-1a 0 (0.0) 2 (3.2) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 3 (2.9)
sc IFN β-1a 0 (0.0) 4 (6.3) 5 (16) 1 (33) 0 (0.0) 0 (0.0) 10 (9.8)
sc IFN β-1b 0 (0.0) 3 (4.8) 0 (0.0) 0 (0.0) 1 (100) 0 (0.0) 4 (3.9)
Fingolimod 0 (0.0) 18 (29) 8 (25) 1 (33) 0 (0.0) 1 (100) 28 (27)
GA 1 (50) 6 (9.5) 4 (12) 0 (0.0) 0 (0.0) 0 (0.0) 11 (11)
Natalizumab 0 (0.0) 20 (32) 9 (28) 1 (33) 0 (0.0) 0 (0.0) 30 (29)
Other 1 (50) 8 (13) 3 (9.4) 0 (0.0) 0 (0.0) 0 (0.0) 12 (12)
No therapy 0 (0.0) 2 (3.2) 2 (6.3) 0 (0.0) 0 (0.0) 0 (0.0) 4 (3.9)
IMPORTANCE OF TREATMENT IN RESPECT TO PREGNANCY
Very important 1 (50) 13 (21) 9 (28) 0 (0.0) 1 (100) 0 (0.0) 24 (24)
Important 0 (0.0) 19 (30) 10 (31) 0 (0.0) 0 (0.0) 1 (100) 30 (29)
Not important 1 (50) 31 (49) 12 (38) 3 (100) 0 (0.0) 0 (0.0) 47 (46)
Unspecified 0 (0.0) 0 (0.0) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.0)
FREQUENCY OF DISCUSSING FAMILY PLANNING WITH NEUROLOGIST
At every consultation 1 (50) 22 (35) 5 (16) 0 (0.0) 0 (0.0) 0 (0.0) 28 (27)
Sporadically 0 (0.0) 21 (33) 14 (44) 1 (33) 0 (0.0) 0 (0.0) 36 (35)
Only when asked by patient 0 (0.0) 17 (27) 12 (38) 1 (33) 1 (100) 1 (100) 32 (31)
Never 1 (50) 3 (4.8) 1 (3.1) 1 (33) 0 (0.0) 0 (0.0) 6 (5.9)
HOW DID THEY LEARN OF OPTIONS?
Treating neurologist 1 (50) 45 (71) 28 (88) 1 (33) 1 (100) 1 (100) 77 (75)
GP 0 (0.0) 3 (4.8) 0 (0.0) 0 (0.0) 1 (100) 0 (0.0) 4 (3.9)
MS-Nurse 2 (100) 8 (13) 4 (12) 0 (0.0) 1 (100) 0 (0.0) 15 (15)
Gynaecologist 0 (0.0) 8 (13) 4 (12) 0 (0.0) 1 (100) 1 (100) 14 (14)
Internet 1 (50) 21 (33) 12 (38) 1 (33) 0 (0.0) 0 (0.0) 35 (34)
Information meetings 0 (0.0) 5 (7.9) 0 (0.0) 0 (0.0) 1 (100) 0 (0.0) 6 (5.9)
Other MS patients 0 (0.0) 13 (21) 3 (9.4) 0 (0.0) 0 (0.0) 0 (0.0) 16 (16)
Information not sought 0 (0.0) 12 (19) 2 (6.3) 2 (67) 0 (0.0) 0 (0.0) 16 (16)
Unspecified 0 (0.0) 1 (1.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.0)
n, number; CIS, clinically isolated syndrome; RRMS, relapsing remitting MS; SPMS, secondary progressive MS, DMD, disease modifying drug; im, intramuscular; sc, subcutaneous,
IFN, interferon; GA, glatiramer acetate; GP, general practitioner.
Importance of DMD Choice With Respect
to Pregnancy
Therapy choice with respect to family planning was important
or very important to 31.4% (85/271) of the total population,
compared with 62% (36/58) and 41% (18/44) of patients with a
short or medium-term plan to conceive, respectively.
Pregnancy Related Concerns
Participants in the survey also provided information about
their pregnancy-related concerns. In the total population, 60.9%
(165/271) were concerned about the course of the disease after
pregnancy, compared with 86.2% (50/58) with a short- and 84.1%
(37/44) with a medium-term plan to conceive. The health of the
unborn child was an issue for 46.9% (127/271), compared with
69% (40/58) with a short- and 81.8% (36/44) with amedium-term
plan to conceive. Taking care of the child after birth mattered to
45% (122/271), compared with 60.3% (35/58) with a short- and
54.5% (24/44) with a medium-term plan to conceive. The course
of the disease during pregnancy concerned 43.5% (118/271),
compared with 62.1% (36/58) with a short- and 77.3% (34/44)
with a medium-term plan to conceive. MS therapy options were
an issue for 35.1% (95/271), compared with 44.8% (26/58) with a
short- and 63.6% (28/44) with a medium-term plan to conceive.
Breast feeding mattered to 21.4% (58/271), compared with 36.2%
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(21/58) with a short- and 38.6% (17/44) with amedium-term plan
to conceive.
Use of DMD Therapy Prior to Pregnancy
Patient use of DMD therapies prior to planned (n = 48) and
unplanned (n = 9) pregnancies was determined (Table 3). One
third of patients with planned pregnancies did not use DMD
therapy prior to conceiving (33.3%, 16/48). The most common
DMD therapy used prior to planned pregnancies was sc IFN
β-1a (31.3%, 15/48). This was followed by natalizumab (10.4%,
5/48), sc IFN β-1b (8.3%, 4/48), fingolimod (6.3%, 3/48), GA
(4.2%, 2/48), im IFN β-1a (4.2%, 2/48) and “other” treatments
(2.1%, 1/48). In contrast, 88.9% (8/9) of patients with unplanned
pregnancies used DMDs. The most commonly used DMDs prior
to unplanned pregnancies were fingolimod and GA (22.2%, 2/9),
followed by natalizumab, sc IFN β-1a and sc IFN β-1b (11.1%,
1/9). Only patients who were receiving fingolimod (4.2%, 3/71)
or natalizumab (2.3%, 2/88) planned to switch therapies due to
their plan to conceive.
Use of DMD According to Family Planning
Status
Of those patients being treated with DMDs (92.3%, 250/271),
approximately half (43.2%, 108/250) had no plan to conceive,
followed by short- or medium-term plan (39.2%, 98/250;
Figure 1). None of the participants who were pregnant at the
time of the survey (1.5%, 4/271) were being treated with DMDs.
Most often, patients did not receive therapy due to child-bearing
reasons (42.9%, 9/21); either they wished to conceive (23.8%,
5/21) or were already pregnant (19.0%, 4/21). The remaining
patients did not want treatment (28.6%, 6/21) or cited “other”
reasons (28.6%, 6/21).
Type of DMD Treatment According to Plan
to Conceive
The type of DMD treatment used by survey participants was
evaluated according to their family planning status (Table 4). A
significantly higher proportion of women with a short-term plan
TABLE 3 | Use of DMD prior to pregnancy.
Pregnancy status, n (%)
Therapy Planned
(n = 48)
Unplanned
(n = 9)
Unspecified
(n = 2)
Total
(n = 59)
im IFN β-1a 2 (4.2) 1 (11.1) 0 (0.0) 3 (5.1)
sc IFN β-1a 15 (31.3) 0 (0.0) 1 (50.0) 16 (27.1)
sc IFN β-1b 4 (8.3) 1 (11.1) 0 (0.0) 5 (8.5)
Fingolimod 3 (6.3) 2 (22.2) 0 (0.0) 5 (8.5)
GA 2 (4.2) 2 (22.2) 0 (0.0) 4 (6.8)
Natalizumab 5 (10.4) 1 (11.1) 0 (0.0) 6 (10.2)
“Other” 1 (2.1) 0 (0.0) 0 (0.0) 1 (1.7)
Unspecified 0 (0.0) 1 (11.1) 1 (50.0) 2 (3.4)
No therapy 16 (33.3) 1 (11.1) 0 (0.0) 17 (28.8)
n, number; im, intramuscular; sc, subcutaneous; IFN, interferon; GA, glatiramer acetate.
to conceive (35.2%, 19/54) were treated with injectable therapies
compared with those without plans to conceive (17.6%, 19/108;
p = 0.013 that the two groups are not different). Numerically
fewer patients with a medium-term plan to conceive (20.5%,
9/44) were treated with injectables compared with those with a
short-term plan (35.2%, 19/54; p = 0.108 that the two groups
are not different). In addition, the number of women receiving
oral treatments was numerically greater in those without plans
to conceive (31.5%, 34/108) compared with those with a short-
term (24.1%, 13/54) plan. However, women with a medium-term
plan (34.1%, 15/44) were proportionally more often treated with
oral therapies compared with those without plans to conceive. A
higher proportion of women without plans to conceive (38.0%,
41/108) received natalizumab compared with those with a short-
(29.6%, 16/54) or medium-term (31.8%, 14/44) plan but this did
not reach significance.
Plan to Conceive and DMD Treatment in
Accordance With Age
The majority of participants under 20 years of age (66.7%, 2/3)
had a medium-term plan to conceive, whilst those aged 20–
30 years mostly had a medium- (48.1%, 37/77) or short-term
(33.8%, 26/77) plan to conceive (Table 5). However, the majority
of all other participants, aged over 31 years, had no plans to
conceive (31–40 years, 43.3%, 42/97; 41–45 years, 76.3%, 29/38;
>45 years, 61.5%, 32/52). Overall, participants mostly (60.5%,
164/271) stated that treatment with respect to pregnancy was not
important. This was also true for individual age categories, where
treatment with respect to pregnancy was not important to greater
than 50% of the populations. More specifically, treatment with
respect to pregnancy was very important or important for those
aged 20–30 years, 45.5%; 31–40 years, 37.1%; 41–45 years, 7.9%;
and>45 years, 13.5% (Table 5).
Treatment Recommendations and Time
After Stopping DMD Until Conception in
the Total Population
In total, 28.0% of patients (76/271) stated that their neurologists
made suggestions regarding DMD therapy based on their plans
to conceive at some point during the disease course. Within
this group, injectables were recommended to 48.7% (37/76;
including 28.9% sc IFN β-1a and 23.7% GA), natalizumab to
11.8% (9/76), fingolimod to 5.3% (4/76) and “other” treatments
were recommended to 2.6% (2/76). In addition, 55.3% of
patients (42/76) stated that their neurologists recommended they
should not use fingolimod. They also advised 18.4% (14/76) of
patients not to use teriflunomide, and 17.1% (13/76) not to use
natalizumab, 10.5% (8/76) not to use injectables and 9.2% (7/76)
not to use “other” treatments.
Since being diagnosed with MS, 15.5% (42/271) of the
participants had one child, 21.8% (59/271) had one or more
and 6.3% (17/271) had 2 or more. In addition, 66.4% (180/271)
of participants had no children since MS diagnosis. Of the
59 women with pregnancies, 9 (15.3%) stated that their last
pregnancy was unplanned. Prior to their last pregnancy, 13.6%
(8/59) of patients stopped treatment and contraception at the
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FIGURE 1 | DMD treatment according to plan to conceive. Patients who had no plan to conceive, were pregnant at the time of the survey (“currently pregnant”) or
planned to conceive in less (“short-term plan”) or more (“medium-term plan”) than 2 years were asked to specify whether or not they were using DMD (disease
modifying drug) therapy. Data for patients planning to conceive are expressed as a percentage of the total number of patients that were treated (white bars; n = 250)
or not treated (black bars; n = 21) with DMDs.
TABLE 4 | DMD treatment use among female patients according to their plans to conceive.
Plan to conceive p-valuea
DMD typeb No plan
(n = 108)
Short-termc
(n = 54)
Medium-termd
(n = 44)
N/A
(n = 44)
No plan vs.
short-term plan
No plan vs.
medium-term plan
Short-term vs.
medium-term plan
Injectable
therapies,
n (%)
19
(17.6)
19
(35.2)
9
(20.5)
7
(15.9)
0.013 0.680 0.108
Oral therapies,
n (%)
34
(31.5)
13
(24.1)
15
(34.1)
14
(31.8)
0.327 0.755 0.275
Infusion therapy,
n (%)
41
(38)
16
(29.6)
14
(31.8)
17
(38.6)
0.295 0.475 0.815
Other,
n (%)
14
(13)
6
(11.1)
6
(13.6)
6
(13.6)
0.736 0.911 0.704
aPearson’s chi-squared test at significance level 0.05, two-sided; bSee Methods for DMD groups; c < 2 years; d≥2 years.
The Swiss SmPC for each DMDgives the following recommendations for women of childbearing age:(23) IFN β/glatiramer acetate/DMF, use a reliable contraceptionmethod; natalizumab,
if pregnancy occurs, therapy cessation should be considered; fingolimod, use a reliable contraception method during therapy and within 2 months of therapy cessation; teriflunomide,
use a reliable contraception method and must not be applied in pregnancy (can only become pregnant if teriflunomide blood concentration is <0.02 mg/L).
DMD, disease modifying drug; DMF, dimethyl fumarate; n, number; N/A, not applicable.
same time, 18.6% (11/59) stopped treatment but continued to use
contraception for a period of time afterwards, and 37.3% (22/59),
discontinued DMD treatment when pregnancy was detected. For
the remaining patients (18/59, 30.5%) no information was given
on treatment discontinuation.
For women with short-term plans to conceive, the time period
between stopping MS therapy and conception ranged from 0 to
6 months in 22.5% (9/40), 7 to 12 months in 12.5% (5/40), and
>12 month in 10% (4/40) of patients (Figure 2). Over half of
the women (55%, 22/40) did not specify the time taken between
stopping DMD therapy for MS and conception for unknown
reasons.
DISCUSSION
Over one third of participants from the Swiss Women with
MS patient survey were pregnant or planned to conceive
and nearly all received DMD treatment independent of their
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TABLE 5 | Plan to conceive and DMD treatment in accordance to age.
Age, years, n (%)
<20 20–30 31–40 41–45 >45 Unspecified Total
n = 3 n = 77 n = 97 n = 38 n = 52 n = 4 N = 271
PLAN TO CONCEIVE
No plan 0 (0.0) 11 (14.3) 42 (43.3) 29 (76.3) 32 (61.5) 3 (75.0) 117 (43.2)
Currently pregnant 0 (0.0) 3 (3.9) 0 (0.0) 1 (2.6) 0 (0.0) 0 (0.0) 4 (1.5)
Short-term 0 (0.0) 26 (33.8) 28 (28.9) 3 (7.9) 0 (0.0) 1 (25.0) 58 (21.4)
Medium-term 2 (66.7) 37 (48.1) 4 (4.1) 0 (0.0) 1 (1.9) 0 (0.0) 44 (16.2)
Unspecified 1 (33.3) 0 (0.0) 23 (23.7) 5 (13.2) 19 (36.5) 0 (0.0) 48 (17.7)
DMD TREATMENT
Yes 3 (100) 72 (93.5) 91 (93.8) 34 (89.5) 47 (90.4) 3 (75.0) 250 (92.3)
No 0 (0.0) 5 (6.5) 6 (6.2) 4 (10.5) 5 (9.6) 1 (25.0) 21 (7.7)
IMPORTANCE OF TREATMENT IN RESPECT TO PREGNANCY
(Very) important 1 (33.3) 35 (45.5) 36 (37.1) 3 (7.9) 7 (13.5) 3 (75.0) 85 (31.4)
Not important 2 (66.7) 41 (53.2) 54 (55.7) 31 (81.6) 35 (67.3) 1 (25.0) 164 (60.5)
Not specified 0 (0.0) 1 (1.3) 7 (7.2) 4 (10.5) 10 (19.2) 0 (0.0) 22 (8.1)
n, number; DMD, disease modifying drug.
FIGURE 2 | Time between stopping MS therapy and conception. Survey
participants were asked to specify the duration of time (0–6, 7–12, or >12
months) taken between stopping DMD treatment and terminating the use of
conception, with a view to conceive. Patients who did not give an answer were
placed in the “unspecified” group.
family planning status. Family planning was amongst the most
important factors in context of the disease, and not surprisingly,
more important to women with plans to conceive compared
with the whole population. Major pregnancy-related concerns
included the disease course during and after pregnancy, the
health of the child and treatment options before and during
pregnancy. This, amongst others reasons, is due to the fact that
limited information is currently available on the safety of DMD
use during pregnancy and therefore, pregnancy usually leads to
an inadvertent treatment break.
Therapy choice with respect to pregnancy was important
or very important to the majority of women with a short-
term plan to conceive. For these patients, a numerically higher
proportion used injectable DMDs compared with oral and
infusion therapies. In addition, significantly more women with
a short-term plan used injectables than those without a plan to
conceive. Overall, injectable DMDs were the most commonly
used therapies prior to almost half of all recorded planned
pregnancies, with sc IFN β-1a being the predominantly used
DMD by approximately one third of patients. A further one third
of patients with planned pregnancies did not use DMD treatment
and no patients who were pregnant at the time of the survey were
using DMD therapy.
Oral therapies (fingolimod and teriflunomide) and
natalizumab were proportionally used more often (not
statistically significant) by women without plans to conceive than
by those with a short- or medium-term plan (natalizumab only).
Of interest, only patients who were treated with fingolimod
or natalizumab planned to switch therapies due to planned
pregnancy.
The predominant use of injectable DMDs prior to planned
pregnancies can likely be attributed to the long-term experience
and studies which have shown that injectable DMDs do not
substantially affect pregnancy outcomes (6, 7). In contrast, the
data on the potential harmful effects of natalizumab and oral
DMDs, in particular fingolimod, explains the restricted use of
these drugs in the context of planned pregnancy (13, 14).
Almost half (49%) of all pregnancies in the USA are
unplanned (21) and given that approximately 15% of pregnancies
in this study were unplanned, the risk of using potentially
teratogenic drugs during early pregnancy should be considered in
women withMS of child-bearing age. In addition, there was often
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a time-lapse between stopping DMD therapy and conception
of more than 6 months. Treatments that have no influence
on pregnancy outcomes would be of major advantage in such
cases, since unplanned pregnancies would not be jeopardised
and treatment gaps lasting uncertain periods of time before
conception could be avoided. These factors may provide further
reasons for the treatment choices observed in this study.
Overall, approximately one third of patients who took part
in the survey were taking natalizumab. This was because the
majority of questionnaires were distributed in a hospital setting.
However, numerically more women without a plan to conceive
used natalizumab compared with those with a short- or medium-
term plan. No patients in this study were treated with DMF,
which reflects the fact that it was only granted authorisation for
use in Switzerland near the beginning of the study (August 2014).
Less than half of patients surveyed reported that the topic
of pregnancy was raised by their neurologist during previous
consultations, with less than one fifth indicating that their
neurologists addressed the issue at every visit. This may explain
the fact that women with plans to conceive often sought
information regarding treatment options and family planning
from alternative sources, including the internet, information
meetings and other MS patients. However, discussing treatment
options in regard to pregnancy should be guided by the treating
neurologist since they have a greater understanding of the MS
treatment options available and their respective safety profiles.
STUDY LIMITATIONS
In order to examine a population that was representative of
female Swiss MS patients, the questionnaire was distributed by
15 Swiss MS centres, 8 of which were hospital-based and 7 were
private practices. However, given that the questionnaire was not
validated and a limited number of patients participated in the
study, with the overall response rate unknown, it is possible that
a subset of patients with a special interest in the topic of family
planning may have responded to the questionnaire. This remains
unclear due to the lack of epidemiological data concerning this
matter in Switzerland.
CONCLUSION
This was the first study to evaluate the role of family planning
in the selection of DMD therapy amongst women with MS,
and the influencing factors that affect therapy choice. The
study highlights that pregnancy remains an important yet
unresolved concern in the treatment of MS patients. This leads
to uncertainty with regard to disease course and the health of
the unborn child. Family planning influences treatment decisions
and in most cases, results in a therapy pause. Since injectables
can be administered until pregnancy occurs (22), the use of
these therapies prevents the need for a therapy pause before
conception.
Taken together, the results of this study provide an
understanding of some factors affecting women with MS
planning a family in order to guide treatment recommendation.
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